Danaher Co. (NYSE:DHR) Shares Bought by Parallel Advisors LLC

Parallel Advisors LLC lifted its stake in Danaher Co. (NYSE:DHR) by 3.4% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 13,524 shares of the conglomerate’s stock after buying an additional 445 shares during the quarter. Parallel Advisors LLC’s holdings in Danaher were worth $3,379,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of DHR. Gilbert & Cook Inc. boosted its holdings in Danaher by 4.9% during the fourth quarter. Gilbert & Cook Inc. now owns 1,830 shares of the conglomerate’s stock worth $423,000 after buying an additional 86 shares in the last quarter. Accretive Wealth Partners LLC boosted its stake in shares of Danaher by 12.9% during the 4th quarter. Accretive Wealth Partners LLC now owns 3,632 shares of the conglomerate’s stock worth $840,000 after acquiring an additional 414 shares in the last quarter. Gryphon Financial Partners LLC grew its position in shares of Danaher by 19.1% during the 4th quarter. Gryphon Financial Partners LLC now owns 2,917 shares of the conglomerate’s stock valued at $675,000 after acquiring an additional 468 shares during the period. Jump Financial LLC increased its stake in shares of Danaher by 287.0% in the 4th quarter. Jump Financial LLC now owns 4,625 shares of the conglomerate’s stock valued at $1,070,000 after purchasing an additional 3,430 shares in the last quarter. Finally, Great Lakes Advisors LLC raised its holdings in Danaher by 23.3% in the 4th quarter. Great Lakes Advisors LLC now owns 43,957 shares of the conglomerate’s stock worth $10,169,000 after purchasing an additional 8,317 shares during the period. 79.05% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Danaher news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the transaction, the senior vice president now owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other Danaher news, CEO Rainer Blair sold 9,007 shares of the company’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the transaction, the chief executive officer now directly owns 97,983 shares in the company, valued at $27,435,240. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the transaction, the senior vice president now owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The disclosure for this sale can be found here. In the last ninety days, insiders sold 39,659 shares of company stock valued at $11,042,433. 11.10% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on DHR shares. Stifel Nicolaus boosted their price objective on Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a research report on Wednesday, July 24th. The Goldman Sachs Group upped their price objective on shares of Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 24th. Barclays lifted their target price on shares of Danaher from $270.00 to $285.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 24th. Bank of America upped their price target on shares of Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 24th. Finally, Jefferies Financial Group started coverage on Danaher in a report on Monday, June 3rd. They issued a “buy” rating and a $295.00 price objective on the stock. Seven research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat.com, Danaher presently has an average rating of “Moderate Buy” and a consensus price target of $278.94.

Danaher Price Performance

Danaher stock opened at $274.25 on Friday. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33. The company has a 50-day moving average price of $264.55 and a 200 day moving average price of $256.50. Danaher Co. has a 12-month low of $182.09 and a 12-month high of $281.70. The stock has a market cap of $198.07 billion, a P/E ratio of 46.48, a PEG ratio of 4.48 and a beta of 0.83.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. The business had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business’s revenue was down 2.9% compared to the same quarter last year. During the same quarter last year, the firm earned $2.05 EPS. Sell-side analysts anticipate that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be issued a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.39%. The ex-dividend date of this dividend is Friday, September 27th. Danaher’s dividend payout ratio is presently 18.31%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.